James Battiste
Neurology · Oklahoma City, OKNPI 1538368881
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 43 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by Novocure Inc. at 59.3% of the total. 2025 is the largest year on record at $783, 6.8 times the $115 reported in 2019.
Across 43 payments — averaging $61.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novocure Inc.$2K
- Servier Pharmaceuticals LLC$189
- Caris MPI, Inc.$166
- AstraZeneca$145
- Amgen$132
- Nobelpharma America, LLC$90
- plus $355 from 8 others
Across 45 payments — averaging $24,146 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$1M
- Jazz Pharmaceuticals Inc.$36K
- Beigene, Ltd.$28K
- AbbVie$22K
What the payments were for
- Food & beverage$2,58598%
- Education$612%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novocure Inc. | 22 | $1,570 |
| Servier Pharmaceuticals LLC | 4 | $189 |
| Caris MPI, Inc. | 2 | $166 |
| AstraZeneca | 2 | $145 |
| Amgen | 1 | $132 |
| Nobelpharma America, LLC | 1 | $90 |
| GSK | 2 | $61 |
| Tesaro, Inc. | 1 | $61 |
| Telix Pharmaceuticals | 1 | $60 |
| Karyopharm Therapeutics Inc. | 1 | $43 |
| UCB, Inc. | 2 | $41 |
| Incyte Corporation | 2 | $40 |
| Medtronic | 1 | $29 |
| Foundation Medicine, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Optune$880
- Oncology$147
- ATACAND$140
- MI CANCER SEEK$133
How this compares
$2,646 in reported general payments places this provider in the 55th percentile of 152 neurology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TibsovoIvosidenib | 52 | $1,452,121 |
| FirdapseAmifampridine Phosphate | 14 | $281,811 |
| KoselugoSelumetinib Sulfate | 14 | $254,316 |
| GleostineLomustine | 13 | $13,947 |
| Lacosamide | 36 | $2,687 |
| Levetiracetam | 50 | $836 |
| Dexamethasone | 45 | $659 |
| Ondansetron Hcl | 51 | $468 |
| Methylphenidate Hcl | 21 | $416 |
| Clonazepam | 27 | $365 |
| Gabapentin | 13 | $358 |
| Hydroxyzine Pamoate | 28 | $292 |
| Prochlorperazine Maleate | 15 | $218 |
| Pantoprazole Sodium | 23 | $188 |
| Nortriptyline Hcl | 12 | $92 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Servier Pharmaceuticals LLCTibsovo | $189 | $1,452,12152 claims |
| AstraZenecaKoselugo | $145 | $254,31614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 152 neurology providers in Oklahoma.
Other neurology in Oklahoma City
- Cherian KarunapuzhaOklahoma City$4.1M
- Gabriel PardoOklahoma City$1.5M
- Marguerite ButcheeOklahoma City$324K
- Chelsea BerkleyOklahoma City$277K
- Mariana VargaOklahoma City$183K
- Aaron FarrowOklahoma City$172K
- Ashish MasihOklahoma City$158K
- Christi PendergraftOklahoma City$73K
- Courtney IserOklahoma City$56K
- Jeanne KingOklahoma City$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.